🚀 VC round data is live in beta, check it out!
Erasca Valuation Multiples
Discover revenue and EBITDA valuation multiples for Erasca and similar public comparables like Shijiazhuang Yiling, Anthem Biosciences, Shanghai Junshi, Crinetics Pharmaceuticals and more.
Erasca Overview
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Founded
2018
HQ
Employees
103
Website
Sectors
Financials (LTM)
EV
$4B
Erasca Financials
Erasca reported last 12-month revenue of — and negative EBITDA of ($149M).
In the same LTM period, Erasca generated — in gross profit, ($149M) in EBITDA losses, and had net loss of ($127M).
Revenue (LTM)
Erasca P&L
In the most recent fiscal year, Erasca reported revenue of — and EBITDA of ($128M).
Erasca expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($149M) | XXX | ($128M) | XXX | XXX | XXX |
| Net Profit | ($127M) | XXX | ($125M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Erasca Stock Performance
Erasca has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Erasca's stock price is $13.65.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 0.0% | XXX | XXX | XXX | $-0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialErasca Valuation Multiples
Erasca trades at (26.7x) EV/EBITDA.
Erasca Financial Valuation Multiples
As of March 21, 2026, Erasca has market cap of $4B and EV of $4B.
Equity research analysts estimate Erasca's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Erasca has a P/E ratio of (33.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/EBITDA | (26.7x) | XXX | (31.1x) | XXX | XXX | XXX |
| EV/EBIT | (27.8x) | XXX | (30.3x) | XXX | XXX | XXX |
| P/E | (33.3x) | XXX | (33.9x) | XXX | XXX | XXX |
| EV/FCF | (86.5x) | XXX | (126.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Erasca Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Erasca Margins & Growth Rates
Erasca's revenue in the last fiscal year grew by —.
Erasca's revenue per employee in the last FY averaged $0.0M.
Erasca Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 24% | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Erasca Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Shijiazhuang Yiling | XXX | XXX | XXX | XXX | XXX | XXX |
| Anthem Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Junshi | XXX | XXX | XXX | XXX | XXX | XXX |
| Crinetics Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Tianjin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Erasca M&A Activity
Erasca acquired XXX companies to date.
Last acquisition by Erasca was on XXXXXXXX, XXXXX. Erasca acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Erasca
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialErasca Investment Activity
Erasca invested in XXX companies to date.
Erasca made its latest investment on XXXXXXXX, XXXXX. Erasca invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Erasca
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Erasca
| When was Erasca founded? | Erasca was founded in 2018. |
| Where is Erasca headquartered? | Erasca is headquartered in United States. |
| How many employees does Erasca have? | As of today, Erasca has over 103 employees. |
| Who is the CEO of Erasca? | Erasca's CEO is Jonathan E. Lim. |
| Is Erasca publicly listed? | Yes, Erasca is a public company listed on Nasdaq. |
| What is the stock symbol of Erasca? | Erasca trades under ERAS ticker. |
| When did Erasca go public? | Erasca went public in 2021. |
| Who are competitors of Erasca? | Erasca main competitors are Shijiazhuang Yiling, Anthem Biosciences, Shanghai Junshi, Crinetics Pharmaceuticals. |
| What is the current market cap of Erasca? | Erasca's current market cap is $4B. |
| Is Erasca profitable? | No, Erasca is not profitable. |
| What is the current EBITDA of Erasca? | Erasca has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Erasca? | Current EBITDA multiple of Erasca is (26.7x). |
| What is the current FCF of Erasca? | Erasca's last 12 months FCF is ($46M). |
| What is the current EV/FCF multiple of Erasca? | Current FCF multiple of Erasca is (86.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.